This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
Nature Communications Open Access 02 February 2024
-
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
Blood Cancer Journal Open Access 28 January 2022
-
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
Blood Cancer Journal Open Access 03 February 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786–2792.
Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008; 141: 615–621.
Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116: 4771–4776.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F . Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014; 89: 1055–1062.
Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester G-R, Scholze J et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. Blood 2002; 100: 3419–3422.
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018–2025.
Hall AM, Vickers MA, McLeod E, Barker RN . Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105: 2007–2015.
Lad DP, Varma S, Varma N, Sachdeva MUS, Bose P, Malhotra P . Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013; 54: 1012–1019.
Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 2016; 30: 346–350.
Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2016; 101: e254–e258.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539–2549.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075–13080.
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D . Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013; 6: 59.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
MB designed the study, supervised the experiments and wrote the manuscript. SS analyzed clinical data, performed the next-generation sequencing preparation and data analysis, and contributed to writing of the manuscript. NA performed next-generation sequencing and data analysis. CF performed next-generation sequencing and data analysis. TM performed the next-generation sequencing preparation. TT and AG provided the data analysis platform. SK provided patient material, interpreted the data and critically revised the manuscript. CB interpreted data and critically revised the manuscript. All authors reviewed the manuscript and approved the final version.
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Schliffke, S., Akyüz, N., Ford, C. et al. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Leukemia 30, 2232–2234 (2016). https://doi.org/10.1038/leu.2016.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.157
This article is cited by
-
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
Nature Communications (2024)
-
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
Blood Cancer Journal (2022)
-
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
Blood Cancer Journal (2017)